• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心源性猝死:全球流行病学与经济视角

Sudden cardiac death: epidemiologic and financial worldwide perspective.

作者信息

Smith Timothy W, Cain Michael E

机构信息

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110-1093, USA.

出版信息

J Interv Card Electrophysiol. 2006 Dec;17(3):199-203. doi: 10.1007/s10840-006-9069-6. Epub 2007 Feb 28.

DOI:10.1007/s10840-006-9069-6
PMID:17333367
Abstract

The term sudden cardiac death (SCD) implies the sudden and unexpected loss of an active, productive member of the community. SCD is typically attributed to lethal ventricular arrhythmias; however, these arrhythmias are impossible to diagnose after the fact. Epidemiologic analyses, therefore, rely on inference of the cause of death. Estimates of the incidence of are SCD variable but it may be as high as 1 per 1,000 per year. The cost of SCD to society is incalculable. Current strategies for preventing SCD rely on risk assessment for cardiology patients and implantation of defibrillators (ICD) in high risk patients. Unfortunately, the absolute number of SCDs that occur in the general (relatively low-risk) population is large compared to the number of SCDs in the high risk population. Therefore, prevention of SCD in high risk populations is unlikely to prevent the majority of SCDs. Cost-effectiveness of ICD implantation for prevention of SCD has been studied; ICDs appear to meet U.S. and European criteria for cost-effectiveness if their benefit extends to at least 7-8 years. However, therapies considered cost-effective may nonetheless be too costly for most worldwide societies. Currently, investigators are focusing on refining risk stratification, partly in hopes of identifying patients for whom ICD implantation will not be useful.

摘要

心脏性猝死(SCD)这一术语意味着社会中一名活跃且有贡献的成员突然意外离世。SCD通常归因于致命性室性心律失常;然而,这些心律失常在事后是无法诊断的。因此,流行病学分析依赖于对死因的推断。SCD发病率的估计值各不相同,但可能高达每年千分之一。SCD给社会带来的成本难以估量。目前预防SCD的策略依赖于对心脏病患者进行风险评估,并对高危患者植入除颤器(ICD)。不幸的是,与高危人群中的SCD数量相比,普通(相对低风险)人群中发生的SCD绝对数量很大。因此,预防高危人群中的SCD不太可能预防大多数SCD。已经对植入ICD预防SCD的成本效益进行了研究;如果ICD的益处至少能持续7至8年,那么它们似乎符合美国和欧洲的成本效益标准。然而,对于世界上大多数社会来说,被认为具有成本效益的治疗方法可能仍然过于昂贵。目前,研究人员正专注于完善风险分层,部分希望是识别出那些ICD植入无用的患者。

相似文献

1
Sudden cardiac death: epidemiologic and financial worldwide perspective.心源性猝死:全球流行病学与经济视角
J Interv Card Electrophysiol. 2006 Dec;17(3):199-203. doi: 10.1007/s10840-006-9069-6. Epub 2007 Feb 28.
2
Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government.对植入式除颤器治疗无反应的心脏性猝死:临床医生、行业和政府的紧迫目标。
J Interv Card Electrophysiol. 2005 Nov;14(2):71-8. doi: 10.1007/s10840-005-4547-9.
3
Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children with Cardiac Conditions Associated with Risk for Sudden Cardiac Death.植入型心律转复除颤器在伴有心源性猝死风险的心脏疾病患儿中的成本效益。
Pediatr Cardiol. 2020 Oct;41(7):1484-1491. doi: 10.1007/s00246-020-02395-y. Epub 2020 Jul 4.
4
Implantable cardioverter defibrillators for prevention of sudden cardiac death.用于预防心源性猝死的植入式心脏复律除颤器
Clin Cardiol. 2007 Jan;30(1):3-8. doi: 10.1002/clc.20001.
5
Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.安大略省年轻人肥厚型心肌病相关心源性猝死。
Circulation. 2019 Nov 19;140(21):1706-1716. doi: 10.1161/CIRCULATIONAHA.119.040271. Epub 2019 Oct 21.
6
Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.用于治疗心律失常的植入式心脏复律除颤器和用于治疗心力衰竭的心脏再同步治疗:系统评价与经济学评估
Health Technol Assess. 2014 Aug;18(56):1-560. doi: 10.3310/hta18560.
7
Risk Stratification for Sudden Cardiac Death After Myocardial Infarction.心肌梗死后心源性猝死的风险分层。
Annu Rev Med. 2018 Jan 29;69:147-164. doi: 10.1146/annurev-med-041316-090046.
8
Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.>or= 表示大于等于,因此译文为: 植入式心脏复律除颤器在年龄大于等于 65 岁患者中的成本效益。
Am Heart J. 2010 Jul;160(1):122-31. doi: 10.1016/j.ahj.2010.04.021.
9
A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.对不同患者群体中植入式心脏复律除颤器治疗的效果和成本相关证据的综述,以及在英国背景下对这些群体的成本效益和成本效用进行建模。
Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. doi: 10.3310/hta10270.
10
Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.利用 2014 年欧洲心脏病学会指南预测植入式心脏复律除颤器的日本肥厚型心肌病患者的治疗方法。
Heart Vessels. 2021 Jan;36(1):99-104. doi: 10.1007/s00380-020-01668-z. Epub 2020 Jul 15.

引用本文的文献

1
Lactate versus Phosphate as Biomarkers to Aid Mechanical Circulatory Support Decisions in Patients with Out-of-Hospital Cardiac Arrest and Return of Spontaneous Circulation.乳酸与磷酸盐作为生物标志物辅助院外心脏骤停并恢复自主循环患者的机械循环支持决策
Diagnostics (Basel). 2023 Apr 24;13(9):1523. doi: 10.3390/diagnostics13091523.
2
Computational Model for Therapy Optimization of Wearable Cardioverter Defibrillator: Shockable Rhythm Detection and Optimal Electrotherapy.可穿戴式心脏复律除颤器治疗优化的计算模型:可电击心律检测与最佳电疗法
Front Physiol. 2021 Dec 10;12:787180. doi: 10.3389/fphys.2021.787180. eCollection 2021.
3

本文引用的文献

1
Growing debate as doctors train on new devices.随着医生使用新设备进行培训,相关争论日益激烈。
N Y Times Web. 2006 Aug 1:A1, C6.
2
The cost of implantable defibrillators: perceptions and reality.植入式心脏除颤器的成本:认知与现实
Eur Heart J. 2007 Feb;28(4):392-7. doi: 10.1093/eurheartj/ehl166. Epub 2006 Aug 3.
3
Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks?植入式心脏复律除颤器用于心力衰竭猝死的一级预防:物有所值吗?
Effect of ventricular myocardium characteristics on the defibrillation threshold.
心室心肌特性对除颤阈值的影响。
Technol Health Care. 2018;26(S1):241-248. doi: 10.3233/THC-174599.
4
Mild therapeutic hypothermia in patients resuscitated from out-of-hospital cardiac arrest: A meta-analysis of randomized controlled trials.院外心脏骤停复苏患者的轻度治疗性低温:随机对照试验的荟萃分析。
Ann Card Anaesth. 2016 Jan-Mar;19(1):4-14. doi: 10.4103/0971-9784.173013.
5
Therapeutic benefits of mild hypothermia in patients successfully resuscitated from cardiac arrest: A meta-analysis.心脏骤停后成功复苏患者亚低温治疗的疗效:一项荟萃分析。
World J Emerg Med. 2013;4(4):260-5. doi: 10.5847/wjem.j.issn.1920-8642.2013.04.003.
6
Cost-effectiveness of implantable cardioverter-defibrillator in today's world.当今世界植入式心脏复律除颤器的成本效益
Indian Heart J. 2014 Jan-Feb;66 Suppl 1(Suppl 1):S101-4. doi: 10.1016/j.ihj.2013.12.034. Epub 2013 Dec 31.
7
Genetic Polymorphisms as Risk Stratification Tool in Primary Preventive ICD Therapy.基因多态性作为原发性预防性植入式心律转复除颤器治疗中的风险分层工具
ISRN Cardiol. 2011;2011:457247. doi: 10.5402/2011/457247. Epub 2011 Apr 18.
8
Electrocardiographic QT interval and mortality: a meta-analysis.心电图 QT 间期与死亡率:荟萃分析。
Epidemiology. 2011 Sep;22(5):660-70. doi: 10.1097/EDE.0b013e318225768b.
9
Cardiac mitochondria and arrhythmias.心脏线粒体与心律失常。
Cardiovasc Res. 2010 Nov 1;88(2):241-9. doi: 10.1093/cvr/cvq231. Epub 2010 Jul 9.
10
Device therapy to prevent sudden death in patients with structural heart disease.用于预防结构性心脏病患者猝死的器械治疗。
Indian Pacing Electrophysiol J. 2010 Jun 5;10(6):239-47.
Circulation. 2006 Jul 11;114(2):101-3. doi: 10.1161/CIRCULATIONAHA.106.637405.
4
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).除颤器治疗或胺碘酮用于慢性稳定型心力衰竭的成本效益:心力衰竭心脏性猝死试验(SCD-HeFT)的结果
Circulation. 2006 Jul 11;114(2):135-42. doi: 10.1161/CIRCULATIONAHA.105.581884. Epub 2006 Jul 3.
5
Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.在符合MADIT-II标准的人群中,用于植入式心脏复律除颤器植入的微伏级T波交替变化筛查策略的成本效益。
J Am Coll Cardiol. 2006 Jul 4;48(1):112-21. doi: 10.1016/j.jacc.2006.02.051. Epub 2006 Jun 9.
6
The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators.接受植入式心脏复律除颤器的医疗保险受益人中主要并发症的发生率及增量成本。
J Am Coll Cardiol. 2006 Jun 20;47(12):2493-7. doi: 10.1016/j.jacc.2006.02.049. Epub 2006 May 30.
7
The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.植入式心脏复律除颤器的成本效益:多中心自动除颤器植入试验(MADIT-II)的结果。
J Am Coll Cardiol. 2006 Jun 6;47(11):2310-8. doi: 10.1016/j.jacc.2006.03.032. Epub 2006 May 4.
8
Cost-effectiveness of implantable cardioverter-defibrillators.植入式心脏复律除颤器的成本效益
N Engl J Med. 2005 Oct 6;353(14):1471-80. doi: 10.1056/NEJMsa051989.
9
[Incidence rate of sudden death in Japan].[日本的猝死发生率]
Nihon Rinsho. 2005 Jul;63(7):1127-34.
10
The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators.患者寿命与植入式心脏复律除颤器使用寿命之间日益增大的不匹配。
J Am Coll Cardiol. 2005 Jun 21;45(12):2022-5. doi: 10.1016/j.jacc.2005.02.077.